


Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Henrik H Hansen¹, Rikke V Grønlund¹, Tamara Baader-Pagler², Peter Haebel², Harald Tammen³, Leif Kongskov Larsen¹, Jacob Jelsing¹, Niels Vrang¹, Thomas Klein²

¹Gubra, Hørsholm, Denmark; ²Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co., Biberach, Germany; ³PXBioVisioN, Hannover, Germany.



Supplementary Figure 1. Terminal (4hrs post-dosing) plasma concentrations of various metabolic markers in DIO mice following 14 days of treatment with vehicle (SC) or linagliptin (3 mg/kg/day, SC). **(A)** C-peptide, **(B)** Glucagon, **(C)** Amylin, **(D)** Leptin, **(E)** Total PYY, **(F)** Pancreatic polypeptide, **(G)** Resistin, **(H)** IL-6, **(I)** MCP-1, **(J)** TNF- α . * $p < 0.05$ vs. vehicle control (unpaired t-test).